Prostate Cancer Reports



Volume 3 Number 8
August 2015
Home > Prostate Cancer Reports > Volume 3, Year 2015 > Number 8, August

CONTENTS

Castration-resistant prostate cancer (CRPC)
Background
Definition of progressing prostate cancer after castration
Assessing treatment outcome in castration-resistant PCa (CRPC)
PSA level as marker of response
Androgen deprivation in castration-resistant PCa
Randomised Phase III Controlled Trials - First-Line Treatment of mCRPC
Docetaxel
Abiraterone
Enzalutamide
Sipuleucel-T



CASTRATION-RESISTANT PROSTATE CANCER


Castration-resistant prostate cancer (CRPC)

Background

Attard G, Cooper CS, de Bono JS.
Steroid hormone receptors in prostate cancer: a hard habit to break?
Cancer Cell. 2009 Dec 8;16(6):458-62. doi: 10.1016/j.ccr.2009.11.006.
Article | PubMed abstract | Full-text PDF | Similar articles


Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T.
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.
Eur Urol. 2009 Oct;56(4):594-605. doi: 10.1016/j.eururo.2009.06.027. Epub 2009 Jun 24.
Article | PubMed abstract | Full-text PDF | Similar articles


Drewa T.
Re: Fritz H. Schröder. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53:1129-37.
Eur Urol. 2009 Jan;55(1):e6-7; author reply e8-9. doi: 10.1016/j.eururo.2008.06.066. Epub 2008 Jun 26.
Article | PubMed abstract | Full-text PDF | Similar articles


Schröder FH.
Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms.
Eur Urol. 2008 Jun;53(6):1129-37. doi: 10.1016/j.eururo.2008.01.049. Epub 2008 Jan 28.
Article | PubMed abstract | Full-text PDF | Similar articles


Whelan P.
Endocrine events in prostate cancer: a paradigm shift in our understanding?
Eur Urol. 2008 Jun;53(6):1101-3. doi: 10.1016/j.eururo.2008.02.001. Epub 2008 Feb 15.
Article | PubMed abstract | Full-text PDF | Similar articles


Definition of progressing prostate cancer after castration

Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group.
Challenges and recommendations for early identification of metastatic disease in prostate cancer.
Urology. 2014 Mar;83(3):664-9. doi: 10.1016/j.urology.2013.10.026. Epub 2014 Jan 8.
Article | PubMed abstract | Similar articles


Cross DS, Ritter M, Reding DJ.
Historical prostate cancer screening and treatment outcomes from a single institution.
Clin Med Res. 2012 Aug;10(3):97-105. doi: 10.3121/cmr.2011.1042. Epub 2012 Apr 25.
Article | PubMed abstract | Full-text PDF | Similar articles


Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
Article | PubMed abstract | Similar articles


Murray NP, Reyes E, Tapia P, Badínez L, Orellana N.
Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an immunocytochemical study.
Bone Marrow Res. 2012;2012:259351. doi: 10.1155/2012/259351. Epub 2012 Nov 26.
Article | PubMed abstract | Full-text PDF | Similar articles


Smith MR, Cook R, Lee KA, Nelson JB.
Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
Cancer. 2011 May 15;117(10):2077-85. doi: 10.1002/cncr.25762. Epub 2010 Nov 16.
Article | PubMed abstract | Full-text PDF | Similar articles


Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS.
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
J Clin Oncol. 2005 May 1;23(13):2918-25.
Article | PubMed abstract | Full-text PDF | Similar articles


Assessing treatment outcome in castration-resistant PCa (CRPC)

Scher HI, Mazumdar M, Kelly WK.
Clinical trials in relapsed prostate cancer: defining the target.
J Natl Cancer Inst. 1996 Nov 20;88(22):1623-34.
Article | PubMed abstract | Full-text PDF | Similar articles


PSA level as marker of response

Bellmunt J, Rosenberg JE, Choueiri TK.
Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.
Eur Urol. 2009 Oct;56(4):606-8. doi: 10.1016/j.eururo.2009.07.015. Epub 2009 Jul 22.
Article | PubMed abstract | Full-text PDF | Similar articles


Dawson NA, McLeod DG.
The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints.
Eur J Cancer. 1997 Apr;33(4):560-5.
Article | PubMed abstract | Similar articles


George DJ, Kantoff PW.
Prognostic indicators in hormone refractory prostate cancer.
Urol Clin North Am. 1999 May 1;26(2):303-10, viii.
Article | PubMed abstract | Similar articles


Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
Article | PubMed abstract | Full-text PDF | Similar articles


Payne H, Cornford P.
Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.
Urol Oncol. 2011 Nov-Dec;29(6):593-601. doi: 10.1016/j.urolonc.2009.11.003. Epub 2010 Jan 8.
Article | PubMed abstract | Full-text PDF | Similar articles


Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
J Natl Cancer Inst. 2006 Apr 19;98(8):516-21.
Article | PubMed abstract | Full-text PDF | Similar articles


Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, et al.
Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.
J Clin Oncol. 1990 Nov;8(11):1830-8.
Article | PubMed abstract | Similar articles


Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol. 2006 Jul 1;24(19):3089-94.
Article | PubMed abstract | Full-text PDF | Similar articles


Smith DC, Dunn RL, Strawderman MS, Pienta KJ.
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.
J Clin Oncol. 1998 May;16(5):1835-43.
Article | PubMed abstract | Similar articles


Androgen deprivation in castration-resistant PCa

Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M.
Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.
J Clin Oncol. 1994 Sep;12(9):1868-75.
Article | PubMed abstract | Similar articles


Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon R, et al.
Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
J Clin Oncol. 1988 Sep;6(9):1456-66.
Article | PubMed abstract | Similar articles


Taylor CD, Elson P, Trump DL.
Importance of continued testicular suppression in hormone-refractory prostate cancer.
J Clin Oncol. 1993 Nov;11(11):2167-72.
Article | PubMed abstract | Similar articles


Randomised Phase III Controlled Trials - First-Line Treatment of mCRPC

Docetaxel

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
N Engl J Med. 2004 Oct 7;351(15):1513-20.
Article | PubMed abstract | Full-text PDF | Similar articles


Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators.
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
N Engl J Med. 2004 Oct 7;351(15):1502-12.
Article | PubMed abstract | Full-text PDF | Similar articles


Abiraterone

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators.
Abiraterone in metastatic prostate cancer without previous chemotherapy.
N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.
Article | PubMed abstract | Full-text PDF | Similar articles


Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F.
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6.
Article | PubMed abstract | Full-text PDF | Similar articles


Suzman D, Eisenberger M.
Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13.
Article | PubMed abstract | Full-text PDF | Similar articles


Enzalutamide

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators.
Enzalutamide in metastatic prostate cancer before chemotherapy.
N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1.
Article | PubMed abstract | Full-text PDF | Similar articles


Sipuleucel-T

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
Article | PubMed abstract | Full-text PDF | Similar articles


Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
J Clin Oncol. 2006 Jul 1;24(19):3089-94.
Article | PubMed abstract | Full-text PDF | Similar articles